Square Pharmaceuticals (SQURPHARMA) Q4 23/24 earnings summary

Executive summary

• Consolidated net revenue rose 15.47% to BDT 70.10 billion for FY 2023-24; consolidated net profit after tax increased 10.26% to BDT 20.93 billion; consolidated EPS reached BDT 23.61.

• Standalone net revenue grew 2.35% to BDT 59.79 billion; standalone net profit after tax declined 5.34% to BDT 15.59 billion; standalone EPS was BDT 17.59.

• Standalone profit and EPS declined due to transfer of several products to Square Lifesciences Ltd., a 99.95% owned subsidiary; consolidated profit and EPS remain unaffected and grew 10.26%.

• Export revenue increased 22.42% to BDT 2.39 billion; 39 new products launched, 28 products transferred to SLL for strategic reasons.

• Dividend payout increased 4.76% to BDT 9.75 billion; recommended cash dividend at 110% of paid-up capital.

Financial highlights

• Consolidated net revenue: BDT 70.10 billion (up 15.47% year-over-year); standalone: BDT 59.79 billion (up 2.35%).

• Consolidated net profit after tax: BDT 20.93 billion (up 10.26%); standalone: BDT 15.59 billion (down 5.34%).

• Consolidated EPS: BDT 23.61 (up 10.26%); standalone EPS: BDT 17.59 (down 5.34%).

• Net operating cash flow per share: BDT 19.96 (up 117.66% year-over-year).

• NAV per share: BDT 119.35 (up 5.25%).

• Export revenue: BDT 2.39 billion (up 22.42%).

Outlook and guidance

• Management expects continued growth driven by new product launches and export market expansion.

• SLL anticipates maintaining its financial growth trajectory with further product launches and export expansion.

• The company remains focused on operational efficiency, R&D, and regulatory compliance to secure long-term sustainability.